MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Sarepta Therapeutics Operating Income 2011-2026 | SRPT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -700 M | 218 M | -268 M | -536 M | -460 M | -564 M | -706 M | -344 M | -172 M | -267 M | -220 M | -134 M | -90.3 M | -29.7 M | -35.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | -706 M | -287 M |
Quarterly Operating Income Sarepta Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | 116 M | -300 M | - | 22.2 M | -701 K | 34.9 M | - | -20.8 M | -134 M | -138 M | - | -131 M | -211 M | -86.9 M | - | -34.5 M | -168 M | -152 M | -171 M | -137 M | -138 M | -118 M | -230 M | -124 M | -275 M | -76.4 M | -139 M | -70.1 M | -103 M | -30.7 M | -23.1 M | -45.9 M | -63.3 M | -39.2 M | -88.4 M | -56.5 M | -62.1 M | -59.7 M | -64.5 M | -51.8 M | -42.1 M | -61.9 M | -44.7 M | -33.7 M | -30.3 M | -25.1 M | -32.8 M | -24.9 M | -17.1 M | -15.4 M | -10.4 M | -6.9 M | -5.56 M | -6.87 M | -9 M | -11.3 M | -10.1 M | -5.53 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 M | -300 M | -70.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.7 | -1.24 % | $ 2.61 B |  USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 166.38 | - | $ 8.28 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.73 | 3.44 % | $ 1.36 B |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.82 | - | $ 1.14 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 26.86 | -3.83 % | $ 719 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-58.5 M | $ 1.02 | - | $ 74.9 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.34 | 0.3 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-472 M | $ 29.2 | -3.41 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 3.8 | -2.06 % | $ 116 M | France |
 |
Alector
ALEC
|
-156 M | $ 2.21 | -9.05 % | $ 228 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-11.1 M | $ 1.37 | -1.44 % | $ 62.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-103 M | $ 4.16 | - | $ 295 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
-50.2 M | $ 13.93 | 0.94 % | $ 5.78 B |  Irlanda |
 |
AbbVie
ABBV
|
15.1 B | $ 234.26 | 0.94 % | $ 414 B | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
-19.9 M | $ 0.77 | -14.64 % | $ 37 M | USA |